On April 1st 2023, the new 5 year contract for Immune Globulin (IG) between Canadian Blood Services and manufacturers went into effect. With this new contract, some changes will be taking place across Canada in regards to certain immune globulin products. We know that some of you have voiced your concern about how these changes will affect you and your care.
IVIG
IVIG patients currently on Gamunex, IVIGnex and Privigen will most likely not see any change in their product.
Panzyga and Octagam
Patients currently on Panzyga or Octagam, should note that these products will no longer be available with a complete phase-out planned. Patients currently on Panzyga or Octagam will be transitioned onto another IVIG product. Please discuss with your prescribing physician. Please note that there will be no exceptional access for this product going forward.
Subcutaneous (SubQ/SCIG)
Patients currently on Cuvitru or Hizentra should not see any changes in their products.
Cutaquig
Patients currently on Cutaquig should note that this product will no longer be available beginning in late 2023 into early 2024. Some patients may be able to stay on Cutaquig for a longer period, all patients will eventually be transitioned to another subcutaneous product. Please discuss with your prescribing physician. Please note that there will be no exceptional access for this product going forward.
We will continue to update you throughout this process, ensuring that patient care is the primary concern. Please know that ImmUnity Canada is working with CBS, blood banks and specialist treaters across Canada to ensure that inconvenience is minimal and access to IG treatment is not disrupted.
Updates will continue to be posted on our website, as well as in our newsletters.
Canadian Blood Services will continue to post updates on their website.